Sign up to save your podcasts
Or
Share The Mechanisms and Role of HIF-PHIs in Patients with CKD and Anemia: Advances in the Therapeutic Landscape, Kidney Colloquium 2nd in the Series
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Mechanisms and Role of HIF-PHIs in Patients with CKD and Anemia: Advances in the Therapeutic Landscape, Kidney Colloquium 2nd in the Series
Patients with CKD and anemia experience substantially increased burdens to morbidity and mortality. The use of erythropoiesis-stimulating agent (ESA) and iron supplementation are mainstays of therapy, yet ESA has been associated with increased cardiovascular adverse events. Furthermore, some patients are resistant to ESA, resulting in higher doses to reach target hemoglobin levels and increasing the risk of adverse events. Increased understanding of hypoxia-inducible factors (HIFs) have led to the development of novel therapies, HIF-PHIs, that work by simulating hypoxia in cells, thereby stimulating EPO synthesis and improving iron metabolism and mobilization through reduced hepcidin levels. Three HIF-PHIs (i.e. roxadustat, vadadustat, and daprodustat) are currently undergoing or have recently completed late-stage development. To be best prepared to incorporate these agents into clinical practice once FDA-approved, nephrologists must be educated on the burdens associated with anemia in CKD, pathophysiological mechanisms involved in CKD-related anemia, and recent outcomes from clinical trials evaluating HIF-PHIs in patients with CKD. This educational activity will address these knowledge gaps among nephrologists, and application of this knowledge will improve outcomes for patients with anemia and CKD.
Earn Credit/ Learning Objectives and Disclosures
https://bit.ly/3fPj151
Integrity Continuing Education designates this podcast for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen.
View all episodes
By Integrity CEPatients with CKD and anemia experience substantially increased burdens to morbidity and mortality. The use of erythropoiesis-stimulating agent (ESA) and iron supplementation are mainstays of therapy, yet ESA has been associated with increased cardiovascular adverse events. Furthermore, some patients are resistant to ESA, resulting in higher doses to reach target hemoglobin levels and increasing the risk of adverse events. Increased understanding of hypoxia-inducible factors (HIFs) have led to the development of novel therapies, HIF-PHIs, that work by simulating hypoxia in cells, thereby stimulating EPO synthesis and improving iron metabolism and mobilization through reduced hepcidin levels. Three HIF-PHIs (i.e. roxadustat, vadadustat, and daprodustat) are currently undergoing or have recently completed late-stage development. To be best prepared to incorporate these agents into clinical practice once FDA-approved, nephrologists must be educated on the burdens associated with anemia in CKD, pathophysiological mechanisms involved in CKD-related anemia, and recent outcomes from clinical trials evaluating HIF-PHIs in patients with CKD. This educational activity will address these knowledge gaps among nephrologists, and application of this knowledge will improve outcomes for patients with anemia and CKD.
Earn Credit/ Learning Objectives and Disclosures
https://bit.ly/3fPj151
Integrity Continuing Education designates this podcast for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen.